Literature DB >> 22720225

Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy.

Pascale Hubert1, Sebastian Amigorena.   

Abstract

Antibody-dependent cell cytotoxicity (ADCC) is critical in monoclonal antibody (mAb)-mediated cancer therapy. We recently showed that a tumor-specific mAb in combination with cyclophosphamide inhibited tumor cell growth and induced ADCC-synapses between tumor and effector cells in vivo, opening perspectives to enhance anti-tumor responses by manipulating the immune system.

Entities:  

Year:  2012        PMID： 22720225      PMCID： PMC3376972          DOI： 10.4161/onci.1.1.17963

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

2.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

4.  In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

Authors:  Simone de Haij; J H Marco Jansen; Peter Boross; Frank J Beurskens; Jantine E Bakema; Desiree L Bos; Anton Martens; J Sjef Verbeek; Paul W H I Parren; Jan G J van de Winkel; Jeanette H W Leusen
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

Review 5.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

6.  Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.

Authors:  Pascale Hubert; Adèle Heitzmann; Sophie Viel; André Nicolas; Xavier Sastre-Garau; Pablo Oppezzo; Otto Pritsch; Eduardo Osinaga; Sebastian Amigorena
Journal:  Cancer Res       Date:  2011-06-22       Impact factor: 12.701

7.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Authors:  E Proietti; G Greco; B Garrone; S Baccarini; C Mauri; M Venditti; D Carlei; F Belardelli
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

8.  Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate.

Authors:  P Y Fung; M Madej; R R Koganty; B M Longenecker
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

9.  T and Tn, general carcinoma autoantigens.

Authors:  G F Springer
Journal:  Science       Date:  1984-06-15       Impact factor: 47.728

10.  Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

Authors:  Veronique Minard-Colin; Yan Xiu; Jonathan C Poe; Mayuka Horikawa; Cynthia M Magro; Yasuhito Hamaguchi; Karen M Haas; Thomas F Tedder
Journal:  Blood       Date:  2008-05-21       Impact factor: 22.113
  10 in total
  11 in total

Review 1.  Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.

Authors:  Henri-Alexandre Michaud; Jean-François Eliaou; Virginie Lafont; Nathalie Bonnefoy; Laurent Gros
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 2.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

3.  Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.

Authors:  P Macor; E Secco; N Mezzaroba; S Zorzet; P Durigutto; T Gaiotto; L De Maso; S Biffi; C Garrovo; S Capolla; C Tripodo; V Gattei; R Marzari; F Tedesco; D Sblattero
Journal:  Leukemia       Date:  2014-06-06       Impact factor: 11.528

4.  Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.

Authors:  Despina Fotiou; Foteini Theodorakakou; Efstathios Kastritis
Journal:  Leuk Res Rep       Date:  2022-05-06

5.  Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.

Authors:  Benjamin Motais; Sandra Charvátová; Zuzana Walek; Matouš Hrdinka; Ryszard Smolarczyk; Tomasz Cichoń; Justyna Czapla; Sebastian Giebel; Michal Šimíček; Tomáš Jelínek; Tereza Ševčíková; Jiří Sobotka; Zdeněk Kořístek; Roman Hájek; Juli R Bagó
Journal:  Cells       Date:  2021-04-21       Impact factor: 6.600

6.  Novel multifunctional antibody approved for the treatment of breast cancer.

Authors:  Domenico Mavilio; Lorenzo Galluzzi; Enrico Lugli
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

Review 7.  Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

Review 8.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

9.  Trial watch: Monoclonal antibodies in cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.

Authors:  Fernando Aranda; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Wolf Hervé Fridman; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-02-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.